Bolt Biotherapeutics (BOLT)

• Market cap: $9.17M
• 1 day: -1.85%
• 5 days: -16.58%
• 1 month: -9.13%
• 3 months: -14.8%
• 6 months: -31.32%
• Year to date: -58.07%
• 1 year: -63.09%
• 5 years: -99.26%
• 10 years: -99.26%
• Sector: Healthcare
• Industry: Biotechnology

About: Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.

Employees: 52